Literature DB >> 19960846

The burden of respiratory syncytial virus bronchiolitis on a pediatric inpatient service.

Arthur I Eidelman1, Orli Megged, Roselyn Feldman, Ori Toker.   

Abstract

BACKGROUND: Respiratory syncytial virus bronchiolitis is the single leading cause of pediatric admissions for infants in the first year of life, presenting regularly in epidemic proportions in the winter months and impacting in major way on pediatric inpatient services.
OBJECTIVES: To quantitate the burden of RSV disease on a pediatric service with the purpose of providing a database for proper health planning and resource allocation.
METHODS: We conducted a prospective 5 year study of documented RSV infections in a single pediatric service. RSV disease was confirmed by direct immunofluorescence testing of nasal swabs from all hospitalized cases of bronchiolitis.
RESULTS: On average, 147 17 cases of RSV bronchiolitis were admitted annually in the November-March RSV season, representing 7%-9% of admissions and 10%-14% of hospital days. There was a consistent male preponderance of admissions (55-64%) and 15-23% of admissions were patients less than 1 month old. In peak months RSS ses accounted for as many of 40% of the hospitalized infants and was the leading cause of over-occupancy (up to 126%) in the pediatric ward during the winter.
CONCLUSIONS: RSV infection is a major burden for pediatric inpatient services during the winter season. This recurrent and predictable "epidemic," which regularly leads to over-occupancy, requires increased manpower (nursing) and resources (beds, pulse oximeters) to facilitate proper care. Since this annual event is not a surprise nor an unexpected peak, but rather a cyclical predictable epidemiological phenomeon, proper planning and allocation of services are crucial.

Entities:  

Mesh:

Year:  2009        PMID: 19960846

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  7 in total

Review 1.  Respiratory syncytial virus-associated hospitalisation in children aged ≤5 years: a scoping review of literature from 2009 to 2021.

Authors:  Michael Noble; Rabia Ali Khan; Brodie Walker; Emma Bennett; Nick Gent
Journal:  ERJ Open Res       Date:  2022-05-30

2.  Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: An evaluation study in Belgium.

Authors:  B Standaert; A Alwan; D Strens; M Raes; M J Postma
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Comparisons between ethnic groups in hospitalizations for respiratory syncytial virus bronchiolitis in Israel.

Authors:  Eias Kassem; Wasef Na'amnih; Amna Bdair-Amsha; Hazar Zahalkah; Khitam Muhsen
Journal:  PLoS One       Date:  2019-04-01       Impact factor: 3.240

4.  Particle and bioaerosol characteristics in a paediatric intensive care unit.

Authors:  Congrong He; Ian M Mackay; Kay Ramsay; Zhen Liang; Timothy Kidd; Luke D Knibbs; Graham Johnson; Donna McNeale; Rebecca Stockwell; Mark G Coulthard; Debbie A Long; Tara J Williams; Caroline Duchaine; Natalie Smith; Claire Wainwright; Lidia Morawska
Journal:  Environ Int       Date:  2017-07-07       Impact factor: 9.621

5.  Increased risk of RSV infection in children with Down's syndrome: clinical implementation of prophylaxis in the European Union.

Authors:  Dianne van Beek; Bosco Paes; Louis Bont
Journal:  Clin Dev Immunol       Date:  2013-06-25

6.  Improving the Hospital Quality of Care during Winter Periods by Optimizing Budget Allocation Between Rotavirus Vaccination and Bed Expansion.

Authors:  Thibaut Dort; Nadia Schecroun; Baudouin Standaert
Journal:  Appl Health Econ Health Policy       Date:  2018-02       Impact factor: 2.561

7.  Incidence and risk factors of hospitalisations for respiratory syncytial virus among children aged less than 2 years.

Authors:  Wasef Na'amnih; Eias Kassem; Shebly Tannous; Viktoria Kagan; Athar Jbali; Elizabeth Hanukayev; Sarit Freimann; Uri Obolski; Khitam Muhsen
Journal:  Epidemiol Infect       Date:  2022-02-02       Impact factor: 2.451

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.